Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
AstraZeneca
Boehringer Ingelheim
McKinsey
Moodys

Last Updated: May 19, 2022

CLINICAL TRIALS PROFILE FOR INSULIN ZINC SUSP PROMPT PURIFIED PORK


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Insulin Zinc Susp Prompt Purified Pork

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00467246 ↗ Sub-Cutaneous Insulin in Hyperglycaemic Emergencies Withdrawn The Royal Bournemouth Hospital N/A 1969-12-31 Hyperglycaemic emergencies are associated with significant mortality (mortality in Diabetic Ketoacidosis 0.65 - 3.3% and in HyperOsmolar Non-Ketotic Coma 12 -17%). To reduce morbidity and mortality, prompt intervention and coma and close monitoring are essential. The study is designed to investigate whether a simple intervention with a long acting insulin can improve resolution of acidosis and hyperglycaemia, prevent recurrence of ketoacidosis and shorten hospital stay.
NCT00657280 ↗ Study of the Effect of Sitagliptin on Glucose (Sugar) Metabolism in Patients With Heart Failure Completed Merck Sharp & Dohme Corp. Early Phase 1 2008-04-01 This study will investigate the effects of sitagliptin, a medicine commonly used to treat type 2 diabetes, on the utilization of glucose by the heart in patients with heart failure which is not due to heart attacks. We hope to determine whether improving the heart's ability to use glucose in the blood may help improve the function of the heart as well. If so, this may suggest that even people who do not have frank diabetes but who do have heart failure may benefit from using this medication. This study will also investigate the effect of sitagliptin on the body's use of sugar, and of the effect of sitagliptin on blood flow to the heart.
NCT00657280 ↗ Study of the Effect of Sitagliptin on Glucose (Sugar) Metabolism in Patients With Heart Failure Completed Stanford University Early Phase 1 2008-04-01 This study will investigate the effects of sitagliptin, a medicine commonly used to treat type 2 diabetes, on the utilization of glucose by the heart in patients with heart failure which is not due to heart attacks. We hope to determine whether improving the heart's ability to use glucose in the blood may help improve the function of the heart as well. If so, this may suggest that even people who do not have frank diabetes but who do have heart failure may benefit from using this medication. This study will also investigate the effect of sitagliptin on the body's use of sugar, and of the effect of sitagliptin on blood flow to the heart.
NCT01016509 ↗ Tight Glycemic Control During Angioplasty Revascularization Reduces Coronary Stent Restenosis Completed Second University of Naples N/A 2009-12-01 A multicentric study will evaluate whether peri-procedural tight glycemic control during angioplasty revascularization for acute coronary syndrome (ACS) reduces circulating inflammatory cytokines and thrombus formation in hyperglycaemic patients. Moreover, the investigators will assess whether the tight glycemic control during the first month from coronary event reduces the incidence of coronary stent restenosis at 6-months from PCI.
NCT01016509 ↗ Tight Glycemic Control During Angioplasty Revascularization Reduces Coronary Stent Restenosis Completed University of Campania "Luigi Vanvitelli" N/A 2009-12-01 A multicentric study will evaluate whether peri-procedural tight glycemic control during angioplasty revascularization for acute coronary syndrome (ACS) reduces circulating inflammatory cytokines and thrombus formation in hyperglycaemic patients. Moreover, the investigators will assess whether the tight glycemic control during the first month from coronary event reduces the incidence of coronary stent restenosis at 6-months from PCI.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Insulin Zinc Susp Prompt Purified Pork

Condition Name

Condition Name for Insulin Zinc Susp Prompt Purified Pork
Intervention Trials
Insulin Resistance 2
Diabetes Mellitus 1
Heart Failure, Congestive 1
Insulin Secretion 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Insulin Zinc Susp Prompt Purified Pork
Intervention Trials
Diabetes Mellitus 2
Insulin Resistance 2
Heart Failure 1
Emergencies 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Insulin Zinc Susp Prompt Purified Pork

Trials by Country

Trials by Country for Insulin Zinc Susp Prompt Purified Pork
Location Trials
United States 4
Italy 1
United Kingdom 1
Israel 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Insulin Zinc Susp Prompt Purified Pork
Location Trials
North Carolina 1
District of Columbia 1
New York 1
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Insulin Zinc Susp Prompt Purified Pork

Clinical Trial Phase

Clinical Trial Phase for Insulin Zinc Susp Prompt Purified Pork
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
Phase 2 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Insulin Zinc Susp Prompt Purified Pork
Clinical Trial Phase Trials
Completed 5
Unknown status 2
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Insulin Zinc Susp Prompt Purified Pork

Sponsor Name

Sponsor Name for Insulin Zinc Susp Prompt Purified Pork
Sponsor Trials
Novartis Pharmaceuticals 1
Royal Devon and Exeter NHS Foundation Trust 1
American Diabetes Association 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Insulin Zinc Susp Prompt Purified Pork
Sponsor Trials
Other 11
Industry 3
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
McKesson
Mallinckrodt
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.